Inc., USA has launched the Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), a product that is bioequivalent and ...

Glenmark Pharmaceuticals' subsidiary has introduced Latanoprost ophthalmic solution, a generic medication for glaucoma, in ...

Glenmark launches Latanoprost Ophthalmic Solution, targeting $113.5 million market, showcasing commitment to quality eye care ...

Glenmark Pharma introduces generic Xalatan ophthalmic solution, 0.005% in US: Our Bureau, Mumbai Friday, February 14, 2025, 12:15 Hrs [IST] Glenmark Pharmaceuticals Inc., USA (Gle ...

Occasionally, treatments come along that are of greater interest to patients than to doctors.Drops for treating presbyopia ...

Inc., USA (Glenmark) has announced the launch of Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), further strengthening its presence in the ophthalmic segment. This latest product is ...

Glenmark Pharmaceuticals launches a generic ophthalmic solution for glaucoma in the US market, adding to its growing ...

According to IQVIA sales data for the 12-month period ending December 2024, the Xalatan Ophthalmic Solution, 0.005% market achieved annual sales of approximately $113.5 million.

New Delhi: Glenmark Pharmaceuticals on Friday said its subsidiary has launched generic medication to treat glaucoma in the US ...

Glenmark Pharmaceuticals said that US-based Glenmark Pharmaceuticals Inc. has launched Latanoprost Ophthalmic Solution.